Q-omics provides the consensus-scored STAG1 profile across patient tissues and cancer cell-line models. STAG1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAG1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, STAG1 protein abundance shows 28,210 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where STAG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAG1 survival associations across molecular data types. STAG1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAG1 RNA expression–survival associations across cancer types. High STAG1 expression shows unfavorable associations in ACC, BLCA, LUSC and PAAD, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAG1 RNA expression.
This table summarizes STAG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STAG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAG1 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and LUSC. The HNSC box plot shows higher STAG1 RNA expression in tumor versus normal tissue (log2 FC = +0.615, t-test p < 0.001).
This table shows molecular features associated with STAG1 in patient tissues and cancer cell lines. In patient samples, STAG1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, STAG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
